scholarly journals Renal cystic lesions characterization using spectral detector CT (SDCT): Added value of spectral results

2019 ◽  
Vol 92 (1100) ◽  
pp. 20180915 ◽  
Author(s):  
Rivka Kessner ◽  
Nils Große Hokamp ◽  
Les Ciancibello ◽  
Nikhil Ramaiya ◽  
Karin A. Herrmann

Objectives: To evaluate the added value of spectral results derived from Spectral Detector CT (SDCT) to the characterization of renal cystic lesions (RCL). Methods: This retrospective study was approved by the local Institutional review board. 70 consecutive patients who underwent abdominopelvic SDCT and had at least one RCL were included. 84 RCL were categorized as simple, complex or neoplastic based on attenuation values on single-phase post-contrast images. Attenuation values were measured in each lesion on standard conventional CT images (stCI) and virtual monoenergetic images of 40keV and 100keV. A spectral curve slope was calculated and intra lesional iodine concentration (IC) was measured using iodine-density maps. Reference standard was established using histopathologic correlation, prior and follow-up imaging. Analysis of variance (ANOVA) was used to compare between the groups. Results: Mean attenuation values for benign simple and complex RCL differed significantly (42 ± 16 vs 8 ± 3 HU; p < 0.001). IC was almost identical in benign simple and complex RCL (0.23 ± 0.04 mg ml−1 vs 0.24 ± 0.04 mg ml−1), while IC in neoplastic RCL was significantly higher (2.10 ± 0.08 mg ml−1 ; p < 0.001). The mean spectral curve slope did not differ significantly between simple and complex RCL (0.30 ± 0.03 vs 0.33 ± 0.05) but was significantly higher in neoplastic RCL (2.60 ± 0.10; p < 0.001). Conclusions: Spectral results of SDCT are highly promising in distinguishing benign complex RCL from enhancing neoplastic RCL based on single-phase post-contrast imaging only. Advances in knowledge: SDCT can assist in differentiating between benign complex and neoplastic renal cystic lesions.

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii356-iii356
Author(s):  
Fatema Malbari ◽  
Murali Chintagumpala ◽  
Jack Su ◽  
Mehmet Okcu ◽  
Frank Lin ◽  
...  

Abstract BACKGROUND Patients with chiasmatic-hypothalamic low grade glioma (CHLGG) have frequent MRIs with gadolinium based contrast agents (GBCA) for disease monitoring. Cumulative gadolinium deposition in children is a potential concern. The purpose of this research is to establish whether MRI with GBCA is necessary for determining tumor progression in children with CHLGG. METHODS Children with progressive CHLGG were identified from Texas Children’s Cancer Center between 2005–2019. Pre- and post-contrast MRI sequences were separately reviewed by one neuroradiologist who was blinded to the clinical course. Three dimensional measurements and tumor characteristics were collected. Radiographic progression was defined as a 25% increase in size (product of two largest dimensions) compared to baseline or best response after initiation of therapy. RESULTS A total of 28 patients with progressive CHLGG including 683 MRIs with GBCA (mean 24 MRIs/patient; range: 10–43 MRIs) were reviewed. No patients had a diagnosis of NF1. Progression was observed 92 times, 91 (98.9%) on noncontrast and 90 (97.8%) on contrast imaging. Sixty-seven radiographic and/or clinical progressions necessitating management changes were identified in all (100%) noncontrast sequences and 66 (98.5%) contrast sequences. Tumor growth &gt;2 mm in any dimension was identified in 184/187(98.4%) on noncontrast and 181/187(96.8%) with contrast imaging. Non primary metastatic disease was seen in seven patients (25%), which were better visualized on contrast imaging in 4 (57%). CONCLUSION MRI without GBCA effectively identifies patients with progressive disease. One should consider eliminating contrast in imaging of children with CHLGG with GBCA reserved for monitoring those with metastatic disease.


2018 ◽  
Vol 211 (3) ◽  
pp. 571-579 ◽  
Author(s):  
Bhavik N. Patel ◽  
Michael Rosenberg ◽  
Federica Vernuccio ◽  
Juan Carlos Ramirez-Giraldo ◽  
Rendon Nelson ◽  
...  

2019 ◽  
Vol 22 (8) ◽  
pp. 673-677
Author(s):  
Mauricio Tobón Restrepo ◽  
Raúl Altuzarra ◽  
Yvonne Espada ◽  
Elisabet Domínguez ◽  
Claudia Mallol ◽  
...  

Objectives The aim of this study was to investigate the frequency of identification and to describe the CT features of the os penis in cats without genitourinary disorders. Methods CT studies from cats that underwent an abdominal or pelvic examination between October 2013 and May 2019 were reviewed retrospectively. Cats with no signs of urinary disease and with the external genitalia included in the scan were recruited. Length, width, height and pre- and post-contrast attenuation values of the os penis in soft tissue and bone algorithms were measured independently by two observers. Results Twenty-three cats met the inclusion criteria. A cylindrical bone-attenuating structure inside the glans penis compatible with the os penis was visible in 20/23 (87%) cats. Mean length, width and height values were 3.48 mm × 1.41 mm × 1.37 mm in the soft tissue algorithm, and 3.26 mm × 1.15 mm × 1.06 mm in bone algorithm. The size of the os penis was not significantly different in neutered vs intact cats, but it was significantly larger in soft tissue vs bone algorithm. Age and body weight did not influence os penis size. Pre-contrast mean ± SD attenuation was 216.7 ± 69.5 Hounsfield units (HU) for soft tissue and 320.1 ± 135.9 HU for bone algorithms. Post-contrast attenuation was 289.1 ± 68.8 HU for soft tissue and 383.4 ± 130.9 HU for bone algorithms. A significant correlation between the attenuation in bone algorithm with body weight was noted, where the os penis was less attenuating with increased body weight (pre-contrast: r = –0.479; P = 0.038). Conclusions and relevance The feline os penis is commonly seen on CT images, being more frequently detected than on radiographs. Its presence should not be mistaken for uroliths in the penile urethra.


2019 ◽  
Vol 39 (6) ◽  
pp. 384-392
Author(s):  
Magnus Lundin ◽  
Peder Sörensson ◽  
Liya Vishnevskaya ◽  
Eva Maret ◽  
Peter Kellman ◽  
...  

QJM ◽  
2020 ◽  
Vol 113 (Supplement_1) ◽  
Author(s):  
A K M Darwish ◽  
M M Farouk ◽  
H Hafez ◽  
A Adel

Abstract Background Iodine concentration is one of the main determinants of arterial enhancement in CTA, and current low-osmolar and iso-osmolar nonionic CM for intravascular administration still come in a handful of molecules, but a relatively wide range of different iodine concentrations. This gives the opportunity to optimize CTA protocols as a function of several factors such as patient characteristics, CT technology, and CM features in an attempt to maximize the diagnostic yield of CTA examinations while considering patient safety and avoiding unnecessary extra costs. Objective To compare image quality and attenuation values of multidetector CT coronary angiography (MDCT) between iopromide 300 and iopromide 370 and to evaluate whether the higher iodine contrast material has better image quality or not. Material and Methods Patients were prospectively enrolled and were randomized into two groups (group A, 30 patients received iopromide 300, iodine flux 1.2g I/s; group B, 30 patients received iomeprol 370, iodine flux 1.48g I/s). CT attenuation values were measured in the proximal end coronary arteries,ascending aorta and main pulmonary artery. The image quality of 15 coronary artery segments was graded by cardiologist in consensus with the use of a four-point scale (1 excellent enhancement to 4 poor enhancement). Non-parametric statistical approaches were used to compare the two groups. Results No statistically significant differences were found between the mean attenuation values (302 HU for iopromide 300 and 326 HU for iopromide 370, P = 0.175) in the coronary arteries in the two groups. The mean attenuation value of the proximal ascending aorta (AA)and main pulmonary artery (MPA) was found to be 345+/-63 HU and 241+/- 89 in group A respectively, whereas the mean attenuation value in proximal ascending aorta and main pulmonary artery in group B was found to be 348+/-74 and 238+/- 50 respectively. No significant difference was found between iopromide 300 and iopromide 370 in terms of contrast enhancement at the level of great arteries, P value AA = 0.826 and P value for MPA = 0.884. 92.9% of coronary arterial segments got score (range 1–2) in group A whereas 93.6 of coronary arterial segments got score (range 1-2) in group with no statistically significant difference P value = 0.755. Conclusion With the current CT technology iopromide 300 is not inferior to iopromide 370 in terms of coronary artery attenuation values and image quality. Iopromide 300 provides similar enhancement of coronary arteries and excellent image quality as compared with iopromide 370 using identical amount of total iodine with fewer cost and less estimated adverse effects owing to low iodine concentration of iopromide 300.


2013 ◽  
Vol 21 (14) ◽  
pp. 17340 ◽  
Author(s):  
J. Rizzi ◽  
P. Mercère ◽  
M. Idir ◽  
P. Da Silva ◽  
G. Vincent ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document